Cardiovascular diseases remain a global health crisis, spurring an urgent demand for innovative diagnostic tools that enable early detection and effective treatment.

This study provides insights into antibacterial components that could be combined with naturally derived materials through a facile Schiff base reaction, offering a potential strategy to enhance antibacterial properties.

After three successful years of raising awareness of the importance of good hormone health through European Hormone Day, the European Society of Endocrinology (ESE) and the European Hormone and Metabolism Foundation (ESE Foundation), have announced the first-ever World Hormone Day to take place on April 24, 2025.

Researchers at Korea University have achieved a significant breakthrough in regenerative medicine. They have demonstrated how fibroblast growth factor 4 and Ascorbic acid, known as vitamin C, can induce the trans-differentiation of fibroblasts into functional cardiomyocytes. This discovery activates key cellular pathways and offers hope for developing treatments for cardiovascular diseases, the leading cause of death worldwide.

Near-infrared II (NIR-II) photoacoustic imaging (PAI) technology is an emerging biomedical imaging modality characterized by high spatial resolution, deep tissue penetration, and high signal-to-noise ratio. NIR-II PAI enables highly clear real-time monitoring of various physiological and pathological processes and visualizes different biological entities, making it crucial for advancements in life sciences and medicine. NIR-II PAI technology holds significant application potential in disease diagnosis and treatment, particularly in early diagnosis, precise localization, boundary delineation, and monitoring of treatment response for tumors and other conditions. By combining with multimodal or diagnostic-therapeutic integrated molecular probes, this technology enables accurate disease localization and guided treatment, which is crucial for early diagnosis and therapy. This review provides a detailed overview of research progress on NIR-II PAI probes, discussing the emergence and latest developments of various NIR-II PAI probes and their applications in early diagnosis and treatment of tumors, cerebrovascular systems, inflammation, and other tissues. Additionally, it summarizes the development status of these probes and outlines future prospects and challenges.

Malignant tumors remain a serious threat to human health and life and are a major public health problem globally. Herein, we designed and synthesized a novel nucleic acid nanomedicine AS1411-siRNA-LNPs (As@LNPs). Bmi-1 siRNA was coated with cationic liposomes, and a nucleic acid aptamer AS1411 with tumor cell-targeting ability was attached to the outermost layer of the liposomes. The average particle size of As@LNPs was 183 nm, and the polydispersion coefficient was 0.187. The encapsulation rate and drug loading of As@LNPs were 85% and 4.6%, respectively. The average electron mobility of the drug was 2.64 (μ/s)/(V/cm), and the zeta potential of As@LNPs was 33.79 ± 0.78 mV. The microstructure of the nanomedicine was evaluated via transmission electron microscopy. In vitro and in vivo experiments showed that As@LNPs significantly inhibited tumor growth and promoted tumor cell apoptosis. As@LNPs showed favorable biosafety with major tissues and organs, except glomerulus and renal epithelial cells.

A groundbreaking Genomic Press Interview reveals that prepartum bumetanide treatment successfully reverses altered neonatal social communication in a congenic mouse model of fragile X syndrome. However, the treatment shows unexpected effects on later social behavior, suggesting distinct developmental mechanisms and highlighting the importance of intervention timing.